Nagoya City University Hospital
Welcome,         Profile    Billing    Logout  
 5 Trials 
24 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Iida, Shinsuke
DREAMM8, NCT04484623 / 2018-004354-21: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

Jan 2024 - Dec 2024: Market entry for 2L multiple myeloma (based on DREAMM-7 trial)
Jan 2024 - Dec 2024: Regulatory approval in EU for 2L+ multiple myeloma (based on DREAMM-7 trial)
Jan 2024 - Dec 2024: Regulatory approval in US for 2L+ multiple myeloma (based on DREAMM-7 trial)
Hourglass Jul 2024 - Dec 2024 : Acceptance of regulatory submission in Japan for 2L+ multiple myeloma (based on DREAMM-8 trial)
Hourglass Jul 2024 - Dec 2024 : Acceptance of regulatory submission in EU for 2L+ multiple myeloma (based on DREAMM-8 trial)
More
Active, not recruiting
3
302
Europe, Japan, US, RoW
Belantamab mafodotin, Pomalidomide, Dexamethasone, Bortezomib
GlaxoSmithKline
Multiple Myeloma
01/24
10/29
DREAMM-10, NCT06679101: A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

Recruiting
3
520
Europe, Japan, RoW
Belantamab mafodotin, Lenalidomide, Dexamethasone, Daratumumab
GlaxoSmithKline
Multiple Myeloma, Newly Diagnosed Multiple Myeloma
12/30
04/32
BRUIN CLL-322, NCT04965493 / 2021-000043-49: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Active, not recruiting
3
600
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
04/26
01/27
DREAMM 5, NCT04126200 / 2019-001138-32: Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Hourglass Jul 2021 - Dec 2021 : From DREAMM-5 trial in combination with nirogacestat for r/r multiple myeloma
Hourglass Feb 2020 - Mar 2020 : Initiation of P1b sub-study of P2 DREAMM-5 trial in combination with nirogacestat for relapsed/refractory multiple myeloma
Checkmark From DREAMM 5 trial in R/R multiple myeloma patients at ASH 2019
Nov 2019 - Nov 2019: From DREAMM 5 trial in R/R multiple myeloma patients at ASH 2019
Checkmark Initiation of DREAMM-5 trial in r/r multiple myeloma
More
Active, not recruiting
2
209
Europe, Canada, US, RoW
Belantamab mafodotin, GSK3174998, Feladilimab, Nirogacestat, Dostarlimab, Isatuximab, Lenalidomide, Dexamethasone, Pomalidomide
GlaxoSmithKline
Multiple Myeloma
02/29
02/29
iinnovate-1, NCT03215030 / 2021-006038-37: A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma

Completed
1/2
272
Europe, Canada, Japan, US, RoW
Modakafusp alfa, TAK-573, TEV-48573, Dexamethasone
Takeda, Takeda Development Center Americas, Inc.
Multiple Myeloma
07/24
11/24
Gupta, Aditya
TAK-279-PsO-3003, NCT06550076: A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

Recruiting
3
1300
Europe, Canada, Japan, US, RoW
TAK-279
Takeda
Plaque Psoriasis
05/26
05/26
NCT06088043: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment

Active, not recruiting
3
693
Europe, Canada, Japan, US, RoW
TAK-279, Placebo, Apremilast
Takeda
Plaque Psoriasis
08/25
04/26
NCT05674747: Pilot Study of Swift Microwave Device for Onychomycosis

Completed
1/2
39
Canada
Swift Microwave treatment - weekly x 4wks, Swift Microwave treatment - Every other week x 4wks, Swift Microwave treatment - Every other week x 24wks
Mediprobe Research Inc., Emblation Limited
Onychomycosis of Toenail
11/24
11/24
Contact, See Central
DESTINY-Breast05, NCT04622319 / 2020-003982-20: A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy

Jan 2024 - Dec 2024: Data from DESTINY-Breast05 trial for HER2+ post neo-adjuvant breast cancer
Jan 2024 - Dec 2024: Acceptance of of regulatory submission for HER2+ post neo-adjuvant breast cancer (DESTINY-Breast05 trial)
Active, not recruiting
3
1600
Europe, Canada, Japan, US, RoW
DS-8201a, Trastuzumab deruxtecan (T-DXd), T-DM1, Trastuzumab emtansine (T-DM1)
Daiichi Sankyo, AstraZeneca, NSABP Foundation Inc, GBG Forschungs GmbH, Spanish Breast Cancer Research Group (SOLTI)
HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer
12/25
12/30
NCT05547087: A Dose Finding Study of VN-0200

Completed
2
342
Japan
VN-0200
Daiichi Sankyo
Respiratory Syncytial Virus Infections
04/23
02/24
HERTHENA-PanTumor01, NCT06172478: A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Recruiting
2
400
Europe, Japan, US, RoW
HER3-DXd, Patritumab Deruxtecan, U3-1402
Daiichi Sankyo, Merck Sharp & Dohme LLC
Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer, Ovarian Carcinoma, Cervical Cancer, Endometrial Cancer, Bladder Cancer, Esophageal Cancer, Pancreatic Carcinoma, Prostate Cancer
06/25
04/26
NCT04703322: A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in Japan

Active, not recruiting
2
9
Japan
Pexidartinib, TURALIO™, PLX3397
Daiichi Sankyo Co., Ltd.
Tenosynovial Giant Cell Tumor
03/23
05/26
IDeate-Pantumor 01, NCT04145622: Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors

Hourglass Sep 2024 - Sep 2024 : Updated data for adv solid tumors
Recruiting
1/2
250
Japan, US
Ifinatamab deruxtecan (I-DXd)
Daiichi Sankyo, Merck Sharp & Dohme LLC
Advanced Solid Tumor, Malignant Solid Tumor
12/25
03/27
KEYNOTE-D35, NCT05438420: Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors

Recruiting
1/2
120
US, RoW
Q702, Pembrolizumab, KEYTRUDA®
Qurient Co., Ltd., Merck Sharp & Dohme LLC
Esophageal Cancer, Gastric Cancer, Hepatocellular Cancer, Cervical Cancer
10/25
06/26
KEYNOTE-E45, NCT05394103: Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors

Recruiting
1/2
130
US, RoW
Q901, KEYTRUDA® (pembrolizumab)
Qurient Co., Ltd., Merck Sharp & Dohme LLC
Advanced Cancer, Metastatic Cancer
12/25
08/26
DS3939-077, NCT05875168: First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors

Recruiting
1/2
470
Europe, Canada, Japan, US, RoW
DS-3939a
Daiichi Sankyo
Advanced Solid Tumor, Metastatic Solid Tumor
03/26
07/27
U31402-A-U102, NCT03260491: U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer

Checkmark Data from trial for NSCLC
Jan 2021 - Jan 2021: Data from trial for NSCLC
Checkmark Data from trial for EGFRm NSCLC at ESMO 2020
Sep 2020 - Sep 2020: Data from trial for EGFRm NSCLC at ESMO 2020
Recruiting
1
309
Europe, Japan, US, RoW
HER3-DXd (FL-DP), U3-1402, HER3-DXd (CTM-1 Lyo-DP), HER3-DXd (CTM-3 Lyo-DP)
Daiichi Sankyo, Merck Sharp & Dohme LLC
Non-Small Cell Lung Cancer (NSCLC)
03/26
12/26
NCT04648254: Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumor

Active, not recruiting
1
78
US
Q702
Qurient Co., Ltd.
Solid Tumor, Advanced Cancer, Metastatic Cancer
12/24
02/25
TROPION-Lung02, NCT04526691: Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer

Jan 2024 - Dec 2024: Data from TROPION-Lung02 trial for advanced or metastatic NSCLC
Checkmark Interim analysis data from TROPION-Lung02 trial for NSCLC
Aug 2022 - Aug 2022: Interim analysis data from TROPION-Lung02 trial for NSCLC
Active, not recruiting
1
145
Europe, Japan, US, RoW
Datopotamab deruxtecan, Dato-DXd, KEYTRUDA®, pembrolizumab, Carboplatin, Cisplatin
Daiichi Sankyo, Merck Sharp & Dohme LLC
Advanced or Metastatic NSCLC
04/26
04/26
NCT04419532: A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors

Active, not recruiting
1
40
Canada, Japan, US
DS-1055a
Daiichi Sankyo Co., Ltd.
Solid Tumor, Advanced Cancer, Metastatic Solid Tumor
01/26
01/26
U31402-A-U103, NCT04676477: HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer

Active, not recruiting
1
280
Japan, US, RoW
HER3-DXd, U3-1402, Patritumab deruxtecan, Osimertinib
Daiichi Sankyo, AstraZeneca, Merck Sharp & Dohme LLC
Non-Small Cell Lung Cancer (NSCLC)
06/25
02/26
DS1471-079, NCT06074705: A Study of DS-1471a In Subjects With Advanced Solid Tumors

Recruiting
1
80
Japan, US
DS-1471a
Daiichi Sankyo Co., Ltd.
Advanced Solid Tumor
06/27
06/27
NCT05769764: A Study of Prevalence of HER3 Expression in Non-Small Cell Lung Cancer

Completed
N/A
225
US
Archival tissue specimen and immunohistochemistry staining
Daiichi Sankyo, Inc.
Non-small Cell Lung Cancer
04/23
04/23
Iwase, Madoka
PRELUDE, NCT06976944: Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer

Recruiting
2
44
Japan
Pembrolizumab, Paclitaxel, Bevacizumab
Yukinori Ozaki, Merck Sharp & Dohme LLC
Recurrent Triple-Negative Breast Cancer
09/28
09/28
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Iida, Shinsuke
DREAMM8, NCT04484623 / 2018-004354-21: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

Jan 2024 - Dec 2024: Market entry for 2L multiple myeloma (based on DREAMM-7 trial)
Jan 2024 - Dec 2024: Regulatory approval in EU for 2L+ multiple myeloma (based on DREAMM-7 trial)
Jan 2024 - Dec 2024: Regulatory approval in US for 2L+ multiple myeloma (based on DREAMM-7 trial)
Hourglass Jul 2024 - Dec 2024 : Acceptance of regulatory submission in Japan for 2L+ multiple myeloma (based on DREAMM-8 trial)
Hourglass Jul 2024 - Dec 2024 : Acceptance of regulatory submission in EU for 2L+ multiple myeloma (based on DREAMM-8 trial)
More
Active, not recruiting
3
302
Europe, Japan, US, RoW
Belantamab mafodotin, Pomalidomide, Dexamethasone, Bortezomib
GlaxoSmithKline
Multiple Myeloma
01/24
10/29
DREAMM-10, NCT06679101: A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

Recruiting
3
520
Europe, Japan, RoW
Belantamab mafodotin, Lenalidomide, Dexamethasone, Daratumumab
GlaxoSmithKline
Multiple Myeloma, Newly Diagnosed Multiple Myeloma
12/30
04/32
BRUIN CLL-322, NCT04965493 / 2021-000043-49: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Active, not recruiting
3
600
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
04/26
01/27
DREAMM 5, NCT04126200 / 2019-001138-32: Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Hourglass Jul 2021 - Dec 2021 : From DREAMM-5 trial in combination with nirogacestat for r/r multiple myeloma
Hourglass Feb 2020 - Mar 2020 : Initiation of P1b sub-study of P2 DREAMM-5 trial in combination with nirogacestat for relapsed/refractory multiple myeloma
Checkmark From DREAMM 5 trial in R/R multiple myeloma patients at ASH 2019
Nov 2019 - Nov 2019: From DREAMM 5 trial in R/R multiple myeloma patients at ASH 2019
Checkmark Initiation of DREAMM-5 trial in r/r multiple myeloma
More
Active, not recruiting
2
209
Europe, Canada, US, RoW
Belantamab mafodotin, GSK3174998, Feladilimab, Nirogacestat, Dostarlimab, Isatuximab, Lenalidomide, Dexamethasone, Pomalidomide
GlaxoSmithKline
Multiple Myeloma
02/29
02/29
iinnovate-1, NCT03215030 / 2021-006038-37: A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma

Completed
1/2
272
Europe, Canada, Japan, US, RoW
Modakafusp alfa, TAK-573, TEV-48573, Dexamethasone
Takeda, Takeda Development Center Americas, Inc.
Multiple Myeloma
07/24
11/24
Gupta, Aditya
TAK-279-PsO-3003, NCT06550076: A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

Recruiting
3
1300
Europe, Canada, Japan, US, RoW
TAK-279
Takeda
Plaque Psoriasis
05/26
05/26
NCT06088043: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment

Active, not recruiting
3
693
Europe, Canada, Japan, US, RoW
TAK-279, Placebo, Apremilast
Takeda
Plaque Psoriasis
08/25
04/26
NCT05674747: Pilot Study of Swift Microwave Device for Onychomycosis

Completed
1/2
39
Canada
Swift Microwave treatment - weekly x 4wks, Swift Microwave treatment - Every other week x 4wks, Swift Microwave treatment - Every other week x 24wks
Mediprobe Research Inc., Emblation Limited
Onychomycosis of Toenail
11/24
11/24
Contact, See Central
DESTINY-Breast05, NCT04622319 / 2020-003982-20: A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy

Jan 2024 - Dec 2024: Data from DESTINY-Breast05 trial for HER2+ post neo-adjuvant breast cancer
Jan 2024 - Dec 2024: Acceptance of of regulatory submission for HER2+ post neo-adjuvant breast cancer (DESTINY-Breast05 trial)
Active, not recruiting
3
1600
Europe, Canada, Japan, US, RoW
DS-8201a, Trastuzumab deruxtecan (T-DXd), T-DM1, Trastuzumab emtansine (T-DM1)
Daiichi Sankyo, AstraZeneca, NSABP Foundation Inc, GBG Forschungs GmbH, Spanish Breast Cancer Research Group (SOLTI)
HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer
12/25
12/30
NCT05547087: A Dose Finding Study of VN-0200

Completed
2
342
Japan
VN-0200
Daiichi Sankyo
Respiratory Syncytial Virus Infections
04/23
02/24
HERTHENA-PanTumor01, NCT06172478: A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Recruiting
2
400
Europe, Japan, US, RoW
HER3-DXd, Patritumab Deruxtecan, U3-1402
Daiichi Sankyo, Merck Sharp & Dohme LLC
Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer, Ovarian Carcinoma, Cervical Cancer, Endometrial Cancer, Bladder Cancer, Esophageal Cancer, Pancreatic Carcinoma, Prostate Cancer
06/25
04/26
NCT04703322: A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in Japan

Active, not recruiting
2
9
Japan
Pexidartinib, TURALIO™, PLX3397
Daiichi Sankyo Co., Ltd.
Tenosynovial Giant Cell Tumor
03/23
05/26
IDeate-Pantumor 01, NCT04145622: Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors

Hourglass Sep 2024 - Sep 2024 : Updated data for adv solid tumors
Recruiting
1/2
250
Japan, US
Ifinatamab deruxtecan (I-DXd)
Daiichi Sankyo, Merck Sharp & Dohme LLC
Advanced Solid Tumor, Malignant Solid Tumor
12/25
03/27
KEYNOTE-D35, NCT05438420: Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors

Recruiting
1/2
120
US, RoW
Q702, Pembrolizumab, KEYTRUDA®
Qurient Co., Ltd., Merck Sharp & Dohme LLC
Esophageal Cancer, Gastric Cancer, Hepatocellular Cancer, Cervical Cancer
10/25
06/26
KEYNOTE-E45, NCT05394103: Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors

Recruiting
1/2
130
US, RoW
Q901, KEYTRUDA® (pembrolizumab)
Qurient Co., Ltd., Merck Sharp & Dohme LLC
Advanced Cancer, Metastatic Cancer
12/25
08/26
DS3939-077, NCT05875168: First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors

Recruiting
1/2
470
Europe, Canada, Japan, US, RoW
DS-3939a
Daiichi Sankyo
Advanced Solid Tumor, Metastatic Solid Tumor
03/26
07/27
U31402-A-U102, NCT03260491: U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer

Checkmark Data from trial for NSCLC
Jan 2021 - Jan 2021: Data from trial for NSCLC
Checkmark Data from trial for EGFRm NSCLC at ESMO 2020
Sep 2020 - Sep 2020: Data from trial for EGFRm NSCLC at ESMO 2020
Recruiting
1
309
Europe, Japan, US, RoW
HER3-DXd (FL-DP), U3-1402, HER3-DXd (CTM-1 Lyo-DP), HER3-DXd (CTM-3 Lyo-DP)
Daiichi Sankyo, Merck Sharp & Dohme LLC
Non-Small Cell Lung Cancer (NSCLC)
03/26
12/26
NCT04648254: Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumor

Active, not recruiting
1
78
US
Q702
Qurient Co., Ltd.
Solid Tumor, Advanced Cancer, Metastatic Cancer
12/24
02/25
TROPION-Lung02, NCT04526691: Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer

Jan 2024 - Dec 2024: Data from TROPION-Lung02 trial for advanced or metastatic NSCLC
Checkmark Interim analysis data from TROPION-Lung02 trial for NSCLC
Aug 2022 - Aug 2022: Interim analysis data from TROPION-Lung02 trial for NSCLC
Active, not recruiting
1
145
Europe, Japan, US, RoW
Datopotamab deruxtecan, Dato-DXd, KEYTRUDA®, pembrolizumab, Carboplatin, Cisplatin
Daiichi Sankyo, Merck Sharp & Dohme LLC
Advanced or Metastatic NSCLC
04/26
04/26
NCT04419532: A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors

Active, not recruiting
1
40
Canada, Japan, US
DS-1055a
Daiichi Sankyo Co., Ltd.
Solid Tumor, Advanced Cancer, Metastatic Solid Tumor
01/26
01/26
U31402-A-U103, NCT04676477: HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer

Active, not recruiting
1
280
Japan, US, RoW
HER3-DXd, U3-1402, Patritumab deruxtecan, Osimertinib
Daiichi Sankyo, AstraZeneca, Merck Sharp & Dohme LLC
Non-Small Cell Lung Cancer (NSCLC)
06/25
02/26
DS1471-079, NCT06074705: A Study of DS-1471a In Subjects With Advanced Solid Tumors

Recruiting
1
80
Japan, US
DS-1471a
Daiichi Sankyo Co., Ltd.
Advanced Solid Tumor
06/27
06/27
NCT05769764: A Study of Prevalence of HER3 Expression in Non-Small Cell Lung Cancer

Completed
N/A
225
US
Archival tissue specimen and immunohistochemistry staining
Daiichi Sankyo, Inc.
Non-small Cell Lung Cancer
04/23
04/23
Iwase, Madoka
PRELUDE, NCT06976944: Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer

Recruiting
2
44
Japan
Pembrolizumab, Paclitaxel, Bevacizumab
Yukinori Ozaki, Merck Sharp & Dohme LLC
Recurrent Triple-Negative Breast Cancer
09/28
09/28

Download Options